PT-141 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
FDA approved in 2019 based on two Phase 3 trials with 1,267+ premenopausal women showing significant improvements in sexual desire and reduced distress. Well-established safety and efficacy profile. PT-141 is fda-approved (2019) as vyleesi for hypoactive sexual desire disorder in premenopausal women. prescription medication. off-label use for males by some providers.
What Does the Research Say About PT-141?
FDA approved in 2019 based on two Phase 3 trials with 1,267+ premenopausal women showing significant improvements in sexual desire and reduced distress. Well-established safety and efficacy profile.
PT-141 (Bremelanotide) is a Melanocortin receptor agonist. Research interest has focused on its potential effects on increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
What Is the Evidence for PT-141's Mechanism?
Activates melanocortin receptors MC1R and MC4R, with MC4R modulating sexual desire through hypothalamic neural circuits. Engages endogenous melanocortin pathways regulating arousal, desire, and sexual response — a completely different mechanism than PDE5 inhibitors like sildenafil.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for PT-141?
FDA approved in 2019 based on two Phase 3 trials with 1,267+ premenopausal women showing significant improvements in sexual desire and reduced distress. Well-established safety and efficacy profile.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, PT-141 has shown preliminary results.
What Does the Safety Research Show?
Nausea (40% incidence, especially first injection), flushing (20%), injection site reactions (13%), headache (11%). Transient blood pressure increases (2-3 mmHg average). Contraindicated in uncontrolled hypertension.
PT-141 is fda-approved (2019) as vyleesi for hypoactive sexual desire disorder in premenopausal women. prescription medication. off-label use for males by some providers.
What Makes PT-141 Unique in Research?
One of the few FDA-approved peptide therapies and the only medication targeting sexual desire through melanocortin brain pathways rather than vascular mechanisms — treats desire itself, not just physical function.
This differentiator is important because it means PT-141 fills a role that other compounds in its class may not fully replicate.
Bottom Line on PT-141 Research
The evidence base for PT-141 is growing. Key research areas include increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
Stay current with PubMed searches for PT-141 for the latest publications.
Complete Guide
PT-141 (Bremelanotide): Research
Related Reading
- PT-141 Dosage Guide
- PT-141 Benefits
- PT-141 Side Effects
- PT-141 Stacking Guide
- PT-141 Cycle Guide
- ARA-290 Complete Guide
Calculate Your PT-141 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PT-141.
Open Calculator →Research-Grade Sourcing
If you're going to research PT-141, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a Melanocortin receptor agonist. Synthetic α-MSH analog targeting MC1R and MC4R for sexual desire modulation. It is researched for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
What is the recommended PT-141 dosage?
Common dosages: 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month via subcutaneous self-injection. Cycle length: on-demand acute dosing; no continuous cycle required. Half-life: peak effects 15-30 minutes post-injection. Use our peptide calculator for exact reconstitution math.
What are the side effects of PT-141?
Nausea (40% incidence, especially first injection), flushing (20%), injection site reactions (13%), headache (11%). Transient blood pressure increases (2-3 mmHg average). Contraindicated in uncontrolled hypertension.
Is PT-141 safe?
PT-141 has shown a preliminary safety profile in research. FDA-approved (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Prescription medication. Off-label use for males by some providers. All research should follow appropriate safety protocols.